Avidity Biosciences Inc
NASDAQ:RNA

  • LAST PRICE
    28.9900
  • TODAY'S CHANGE (%)
    -0.5200 (-1.7621%)
  • Bid / Lots
    28.9700/ 2
  • Ask / Lots
    29.0200/ 2
  • Open / Previous Close
    29.3200 / 29.5100
  • Day Range
    28.4900
    29.4700
  • 52 Week Range
    4.8250
    30.5400
  • Volume
    769,351

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
RNA
Avidity Biosciences Inc
2.8B
-9.8x
---
CLDX
Celldex Therapeutics Inc
2.6B
-14.1x
---
IOVA
Iovance Biotherapeutics Inc
3.0B
-5.8x
---
MLTX
MoonLake Immunotherapeutics
2.6B
-54.6x
---
XENE
Xenon Pharmaceuticals Inc
3.1B
-15.1x
---
VSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
As of 2024-05-16

Company Information

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Contact Information

Headquarters
10578 SCIENCE CENTER DRIVE, SUITE 125SAN DIEGO, CA, United States 92121
Phone
858-401-7900
Fax
302-636-5454

Executives

Chairman of the Board
Troy Wilson
President, Chief Executive Officer, Director
Sarah Boyce
Chief Financial and Chief Business Officer
Michael Maclean
Chief Human Resource Officer
Teresa Mccarthy
Chief Scientific and Technical Officer
W. Michael Flanagan

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.8B
Revenue (TTM)
$10.9M
Shares Outstanding
95.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.85
EPS
$-2.95
Book Value
$6.32
P/E Ratio
-9.8x
Price/Sales (TTM)
259.6
Price/Cash Flow (TTM)
---
Operating Margin
-2,347.65%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.